Log in

NASDAQ:PMDPsychemedics Stock Price, Forecast & News

$5.79
-0.26 (-4.30 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.70
Now: $5.79
$6.15
50-Day Range
$4.90
MA: $5.52
$6.05
52-Week Range
$4.54
Now: $5.79
$10.69
Volume28,030 shs
Average Volume26,335 shs
Market Capitalization$32.02 million
P/E Ratio41.36
Dividend Yield12.44%
Beta0.85
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PMD
CUSIPN/A
Phone978-206-8220

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.68 million
Cash Flow$0.97 per share
Book Value$3.05 per share

Profitability

Net Income$1.54 million

Miscellaneous

Employees250
Market Cap$32.02 million
Next Earnings Date7/28/2020 (Estimated)
OptionableNot Optionable

Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.

Psychemedics (NASDAQ:PMD) Frequently Asked Questions

How has Psychemedics' stock been impacted by COVID-19 (Coronavirus)?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PMD shares have decreased by 16.7% and is now trading at $5.79. View which stocks have been most impacted by Coronavirus.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Psychemedics.

How were Psychemedics' earnings last quarter?

Psychemedics Corp. (NASDAQ:PMD) released its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company earned $7.54 million during the quarter. Psychemedics had a return on equity of 9.48% and a net margin of 2.14%. View Psychemedics' earnings history.

How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?

Psychemedics declared a quarterly dividend on Tuesday, February 11th. Shareholders of record on Friday, February 21st will be given a dividend of $0.18 per share on Tuesday, March 3rd. This represents a $0.72 annualized dividend and a dividend yield of 12.44%. The ex-dividend date of this dividend is Thursday, February 20th. View Psychemedics' dividend history.

Has Psychemedics been receiving favorable news coverage?

Press coverage about PMD stock has been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Psychemedics earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the near future. View the latest news about Psychemedics.

Who are some of Psychemedics' key competitors?

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Ring Energy (REI), Ring Energy (REI), AT&T (T), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Canopy Growth (CGC), Dominion Energy (D), Pattern Energy Group (PEGI), Athersys (ATHX) and Corbus Pharmaceuticals (CRBP).

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:
  • Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)
  • Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)
  • Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)
  • Dr. Werner A. Baumgartner Ph.D., Founder
  • Ms. Annette Baumgartner, Founder

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $5.79.

How big of a company is Psychemedics?

Psychemedics has a market capitalization of $32.02 million and generates $37.68 million in revenue each year. Psychemedics employs 250 workers across the globe.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.